Rotigotine and parkinsonism-hyperpyrexia syndrome Authors: Shohei Watanabe, Ayano Hasuike, Hosho Morishita, Koji Yagi, Eiko Fujiwara, Daisuke Yamanaka, Shuhei Kasama, Masataka Igeta, Takashi Kimura Published: 2026 ABSTRACT Highlights•Rotigotine showed a tendency to suppress the development of PHS.•Maintaining good medication compliance is crucial for suppressing PHS in PD.•Rotigotine is a once-daily transdermal patch that promotes medication compliance. Introduction Parkinsonism-hyperpyrexia syndrome (PHS) is a potentially life-threatening disorder in patients with Parkinson’s disease (PD). PHS is characterized by hyperthermia, prominent rigidity, disturbance of consciousness, autonomic dysfunction, and elevated serum creatine kinase (CK) [1]. The main triggering event of PHS is antiparkinsonian medication discontinuation or reduction. Other triggering events are also recognized, such as infections, motor fluctuations, and anorexia, which can also unintentionally interrupt oral drug intake [2], [3], [4]. Additionally, it has been reported that PHS is prone to develop in elderly patients with PD with a long disease duration and is predominantly found in males [5], [6]. New drugs for the treatment of PD were recently developed one after another. In particular, rotigotine transdermal patches (dopamine agonists D1-D5) continuously deliver the drug for over 24 h, with the additional advantage of being administered even when oral drug intake is difficult [7], [8]. However, the relationship between the onset of PHS and antiparkinsonian medications has not been sufficiently investigated to date. In this study, we compared the clinical characteristics, including details of antiparkinsonian drugs, between PHS and non-PHS cases during the emergency hospitalization of patients with PD in our institution. In particular, we investigated whether rotigotine suppressed the onset of PHS. Methods Selection of patients and clinical evaluation We retrospectively examined the medical records of 166 episodes of emergency hospitalization of 117 patients with PD at Hyogo Medical University Hospital from January 2010 to December 2024. We confirmed the diagnosis of PD in these patients using the Movement Disorder Society clinical diagnostic criteria [9]. We excluded 19 episodes with insufficient medical information and investigated the medical records of the remaining 147 episodes (114 patients). Since widely accepted diagnostic criteria for PHS have not yet been established, we adopted the modified Levenson diagnostic criteria for neuroleptic malignant syndrome to diagnose PHS (Table 1) [2], [10]. As per Levenson’s criteria, 30 episodes (28 patients) met the PHS diagnostic criteria (PHS group), and 117 episodes (86 patients) that did not meet the criteria (non-PHS group). Two patients experienced recurrent episodes of PHS. We then assessed the following clinical characteristics based on the medical records: sex, age, PD duration, modified Hoehn & Yahr (m H&Y) stage (both on and off states), levodopa (LD) dose, LD equivalent dose (LED) [11], and details of antiparkinsonian medications. Additionally, we assessed the precipitation events of emergency hospitalization in both the PHS and non-PHS groups. “Medication withdrawal/reduction” was defined as being due to the healthcare provider's instructions. On the other hand, “poor medication compliance” was defined as a situation in which a patient fails to adhere to the prescribed medication regimen due to their own actions. Medication compliance was confirmed through interviews with the patients and/or their family.Table 1PHS diagnostic criteria.Major manifestationsFeverExacerbation of parkinsonismElevated CKMinor manifestationsTachycardiaAbnormal blood pressureTachypneaAltered consciousnessDiaphoresisLeukocytosisEnrolment criteriaThe presence of all three major manifestations or two major + four minor onesAbbreviations: CK, creatine kinase; PHS, Parkinsonism-Hyperpyrexia syndrome. Table 1PHS diagnostic criteria.Major manifestationsFeverExacerbation of parkinsonismElevated CKMinor manifestationsTachycardiaAbnormal blood pressureTachypneaAltered consciousnessDiaphoresisLeukocytosisEnrolment criteriaThe presence of all three major manifestations or two major + four minor onesAbbreviations: CK, creatine kinase; PHS, Parkinsonism-Hyperpyrexia syndrome. PHS diagnostic criteria. Abbreviations: CK, creatine kinase; PHS, Parkinsonism-Hyperpyrexia syndrome. This study was approved by the Ethics Committee of the Hyogo Medical University (approval number: 4211). Statistical analysis Continuous variables were summarized as mean ± standard deviation (SD). Categorical variables were presented as frequencies and percentages within each group. Between-group differences were descriptively assessed. Based on a previous literature review [5], we selected the following factors for multivariable analysis to evaluate the effect of rotigotine on PHS: age, PD duration, sex, and rotigotine administration. Multivariable logistic regression based on generalized estimating equations was performed to estimate odds ratios (ORs) for the development of PHS. Because some patients contributed more than one hospitalization episode, within-patient correlation was accounted for by specifying patient-level clustering with an exchangeable working correlation structure. Wald-type confidence intervals (CIs) based on robust sandwich standard errors were calculated for regression coefficients, which were exponentiated to obtain ORs. The threshold for statistical significance was set at p < 0.05. The analyses were performed using EZR (Saitama Medical Center, Jichi Medical University, Japan), a graphical user interface for R (The R Foundation for Statistical Computing, Vienna, Austria) [12], and SAS software (SAS Institute, Cary, NC, USA). Results Clinical characteristics The clinical characteristics of the PHS and non-PHS groups are summarized in Table 2. The age, PD duration, and m H&Y stage of the PHS group were lower than those of the non-PHS group. Furthermore, the PHS group had lower LD and LED. Rotigotine was administered in 5 PHS (dose:10.8 ± 2.5 mg/day, duration of administration:10 ± 6.7 months) and 41 non-PHS (dose: 13.1 ± 5.4 mg/day, duration of administration: 26.7 ± 18.9 months) cases. Eight patients prescribed rotigotine experienced two recurrent episodes and one patient prescribed rotigotine experienced three recurrent episodes of emergency hospitalization due to causes other than PHS (non-PHS cases). One patient prescribed rotigotine experienced a recurrence of PHS. The details of 5 PHS cases prescribed rotigotine are summarized in Table 3.Table 2Patient characteristics.PHS groupNon-PHS groupN30117Sex (male)11 (36.7)55 (47.0)Age, years69.8 ± 7.774.8 ± 7.5PD duration, years8.5 ± 6.811.5 ± 7.0m H & Y stage (ON state)3.9 ± 0.64.3 ± 0.7m H & Y stage (OFF state)4.0 ± 0.64.5 ± 0.6LD dose, mg/day411.7 ± 165.9507.8 ± 294.7LED, mg/day722.0 ± 348.0837.3 ± 516.1Coadministrated anti-PD drugsBromocriptinenone1 (0.9)Pergolide2 (6.7)1 (0.9)Cabergoline1 (3.3)1 (0.9)Pramipexole9 (30.0)27 (23.1)Ropinirole oral2 (6.7)14(12.0)Ropinirole patch1 (3.3)4 (3.4)Rotigotine5 (16.7)41 (35.0)Selegiline7 (23.3)29 (24.8)Rasagilinenone9 (7.7)Safinamide2 (6.7)1 (0.9)Entacapone11 (36.7)29 (24.8)Opicapone2 (6.7)5 (4.3)Amantadine5 (16.7)12 (10.3)Trihexyphenidyl2 (6.7)5 (4.3)Biperidene2 (6.7)1 (0.9)Droxidopa2 (6.7)9 (7.7)Zonisamide8 (26.7)34 (29.1)Istradefylline2 (6.7)18 (15.4)Abbreviations: LD, levodopa; LED, levodopa equivalent dose; m H & Y, modified Hoehn & Yahr; PD, Parkinson’s disease; PHS, Parkinsonism-Hyperpyrexia syndrome.Continuous variables are presented as mean ± standard deviation (SD).Categorical variables are presented as n (%).Table 3Characteristics of PHS cases prescribed rotigotine.Patient numberAgeSexPD duratuion(years)Body temperture(axillary, ℃)CK(U/L)Leukocytes (/µL)rotigotine dose(mg/day)rotigotine duration(months)other anti-PD drugs(mg/day)precipitating events for PHS165F237.86450671095LD 500fall and difficulty moving66337.82494512013.510LD 600fall and difficulty moving275F1040464214,440912LCE 300, AMA 300, ZNS 25poor medication compliance372F2838.961010,98093LCE 200, AMA 300, SEL 5, PRA 1poor food intake and difficulty moving459M2338.429,79311,12013.520LD 450, AMA 200, SEL 5, BIP 1.5,CAB 2.5poor medication complianceAbbreviations: AMA, amantadine; BIP, biperiden; CAB; cabergoline; CK, creatine kinase; LCE, levodopa carbidopa hydrate entacapone; LD, levodopa; PD, Parkinson’s disease; PHS, Parkinsonism-Hyperpyrexia syndrome; PRA, pramipexole; SEL, selegiline; ZNS, zonisamide. Table 2Patient characteristics.PHS groupNon-PHS groupN30117Sex (male)11 (36.7)55 (47.0)Age, years69.8 ± 7.774.8 ± 7.5PD duration, years8.5 ± 6.811.5 ± 7.0m H & Y stage (ON state)3.9 ± 0.64.3 ± 0.7m H & Y stage (OFF state)4.0 ± 0.64.5 ± 0.6LD dose, mg/day411.7 ± 165.9507.8 ± 294.7LED, mg/day722.0 ± 348.0837.3 ± 516.1Coadministrated anti-PD drugsBromocriptinenone1 (0.9)Pergolide2 (6.7)1 (0.9)Cabergoline1 (3.3)1 (0.9)Pramipexole9 (30.0)27 (23.1)Ropinirole oral2 (6.7)14(12.0)Ropinirole patch1 (3.3)4 (3.4)Rotigotine5 (16.7)41 (35.0)Selegiline7 (23.3)29 (24.8)Rasagilinenone9 (7.7)Safinamide2 (6.7)1 (0.9)Entacapone11 (36.7)29 (24.8)Opicapone2 (6.7)5 (4.3)Amantadine5 (16.7)12 (10.3)Trihexyphenidyl2 (6.7)5 (4.3)Biperidene2 (6.7)1 (0.9)Droxidopa2 (6.7)9 (7.7)Zonisamide8 (26.7)34 (29.1)Istradefylline2 (6.7)18 (15.4)Abbreviations: LD, levodopa; LED, levodopa equivalent dose; m H & Y, modified Hoehn & Yahr; PD, Parkinson’s disease; PHS, Parkinsonism-Hyperpyrexia syndrome.Continuous variables are presented as mean ± standard deviation (SD).Categorical variables are presented as n (%). Patient characteristics. Abbreviations: LD, levodopa; LED, levodopa equivalent dose; m H & Y, modified Hoehn & Yahr; PD, Parkinson’s disease; PHS, Parkinsonism-Hyperpyrexia syndrome. Continuous variables are presented as mean ± standard deviation (SD). Categorical variables are presented as n (%). Table 3Characteristics of PHS cases prescribed rotigotine.Patient numberAgeSexPD duratuion(years)Body temperture(axillary, ℃)CK(U/L)Leukocytes (/µL)rotigotine dose(mg/day)rotigotine duration(months)other anti-PD drugs(mg/day)precipitating events for PHS165F237.86450671095LD 500fall and difficulty moving66337.82494512013.510LD 600fall and difficulty moving275F1040464214,440912LCE 300, AMA 300, ZNS 25poor medication compliance372F2838.961010,98093LCE 200, AMA 300, SEL 5, PRA 1poor food intake and difficulty moving459M2338.429,79311,12013.520LD 450, AMA 200, SEL 5, BIP 1.5,CAB 2.5poor medication complianceAbbreviations: AMA, amantadine; BIP, biperiden; CAB; cabergoline; CK, creatine kinase; LCE, levodopa carbidopa hydrate entacapone; LD, levodopa; PD, Parkinson’s disease; PHS, Parkinsonism-Hyperpyrexia syndrome; PRA, pramipexole; SEL, selegiline; ZNS, zonisamide. Characteristics of PHS cases prescribed rotigotine. Abbreviations: AMA, amantadine; BIP, biperiden; CAB; cabergoline; CK, creatine kinase; LCE, levodopa carbidopa hydrate entacapone; LD, levodopa; PD, Parkinson’s disease; PHS, Parkinsonism-Hyperpyrexia syndrome; PRA, pramipexole; SEL, selegiline; ZNS, zonisamide. The ropinirole patch, another dopamine agonist transdermal patch, was administered to only one PHS and four non-PHS cases. Neither bromocriptine nor rasagiline was prescribed to the PHS group. Events leading to emergency hospitalization The events leading to emergency hospitalization are summarized in Table 4. In the PHS group, poor medication compliance was particularly noticeable (n = 11, 36.7%). Meanwhile, the most common event in the non-PHS group was infection (n = 59, 50.4%), especially that of the respiratory tract (n = 38, 32.5%).Table 4Events leading to emergency hospitalization.PHS groupNon-PHS groupN30117Medication withdrawal/reduction1 (3.3)2 (1.7)Because of hallucination1 (3.3)noneskin disordersnone1 (0.9)nauseanone1 (0.9)Poor medication compliance11 (36.7)1 (0.9)Infection5 (16.7)59 (50.4)Respiratory tract1 (3.3)38 (32.5)Urinary tract4 (13.3)11 (9.4)Other regionnone10 (8.5)Motor fluctuations alone1 (3.3)23 19.7)Fall/fracture6 (20.0)7 (6.0)Anorexia/poor food intake2 (6.7)2 (1.7)Dysphagia2 (6.7)noneChokenone4 (3.4)Dehydration1 (3.3)4 (3.4)Ileusnone2 (1.7)Altered consciousnessnone3 (2.6)Hallucinationnone2 (1.7)Others1 (3.3)8 (6.8)Abbreviations: PHS, Parkinsonism-Hyperpyrexia syndrome.Values are presented as n (%). Table 4Events leading to emergency hospitalization.PHS groupNon-PHS groupN30117Medication withdrawal/reduction1 (3.3)2 (1.7)Because of hallucination1 (3.3)noneskin disordersnone1 (0.9)nauseanone1 (0.9)Poor medication compliance11 (36.7)1 (0.9)Infection5 (16.7)59 (50.4)Respiratory tract1 (3.3)38 (32.5)Urinary tract4 (13.3)11 (9.4)Other regionnone10 (8.5)Motor fluctuations alone1 (3.3)23 19.7)Fall/fracture6 (20.0)7 (6.0)Anorexia/poor food intake2 (6.7)2 (1.7)Dysphagia2 (6.7)noneChokenone4 (3.4)Dehydration1 (3.3)4 (3.4)Ileusnone2 (1.7)Altered consciousnessnone3 (2.6)Hallucinationnone2 (1.7)Others1 (3.3)8 (6.8)Abbreviations: PHS, Parkinsonism-Hyperpyrexia syndrome.Values are presented as n (%). Events leading to emergency hospitalization. Abbreviations: PHS, Parkinsonism-Hyperpyrexia syndrome. Values are presented as n (%). Association between PHS and rotigotine In the multivariable analysis, age was significantly negatively associated with the development of PHS (OR, 0.894, 95% CI, 0.840–0.952, p = 0.0005). And rotigotine administration showed a tendency to suppress the development of PHS, although this result did not reach significance (OR, 0.353; 95% CI, 0.121–1.031; p = 0.0569) (Table 5).Table 5Results of multivariable analyses of clinical factors for the onset of PHS.VariableMultivariable OR (95% CI)pSex (Male/Female)0.479 (0.186–1.237)0.1286Age, years0.894 (0.840–0.952)0.0005PD duration, years0.929 (0.846–1.020)0.1201Administration of Rotigotine (Yes/No)0.353 (0.121–1.031)0.0569Abbreviations: CI, confidence interval; OR, odds ratio; PD, Parkinson’s disease; PHS, Parkinsonism-hyperpyrexia syndrome. Table 5Results of multivariable analyses of clinical factors for the onset of PHS.VariableMultivariable OR (95% CI)pSex (Male/Female)0.479 (0.186–1.237)0.1286Age, years0.894 (0.840–0.952)0.0005PD duration, years0.929 (0.846–1.020)0.1201Administration of Rotigotine (Yes/No)0.353 (0.121–1.031)0.0569Abbreviations: CI, confidence interval; OR, odds ratio; PD, Parkinson’s disease; PHS, Parkinsonism-hyperpyrexia syndrome. Results of multivariable analyses of clinical factors for the onset of PHS. Abbreviations: CI, confidence interval; OR, odds ratio; PD, Parkinson’s disease; PHS, Parkinsonism-hyperpyrexia syndrome. Discussion Although not statistically significant, rotigotine tended to be negatively associated with the development of PHS in this study. We hypothesize that rotigotine may have a protective effect against PHS. Rotigotine is a non-ergolinic dopamine agonist (D1-D5) administered via a transdermal patch once a day. Because of the transdermal formulation, rotigotine is absorbed through the skin over 24 h, making it easier to maintain stable plasma concentrations compared to other dopamine agonists administered orally several times a day [7], [13]. Additionally, even when oral administration is not possible or intestinal motility disorders cause poor drug absorption, rotigotine shows a certain degree of efficacy. In our study, the most common precipitation event in PHS was poor medication compliance. Treatment of advanced PD often involves multiple medications, and it is critical to maintain good medication compliance for patients with PD. As rotigotine is a transdermal patch drug administered once daily, it can encourage better medication compliance than can other oral antiparkinsonian drugs. Therefore, we speculated that the use of rotigotine could prevent the onset of PHS. Although the discontinuation or dose reduction of antiparkinsonian drugs was reported to be the most common cause of PHS in previous studies [2], [6], only one such case was found in this study (medication withdrawal/reduction). As the risk of PHS has become widely recognized, abrupt reductions or discontinuations of antiparkinsonian medication by healthcare providers may have decreased. Nevertheless, the risk of sudden dose reduction or discontinuation by patients with PD themselves (particularly those with comorbid dementia or poor medication compliance) remains, and the people around them are often unaware of the discontinuation of medication. Transdermal patch drugs, such as rotigotine, are labeled with the date of administration and are useful for verifying medication compliance. These characteristics of rotigotine may play a role in preventing PHS onset. However, we found 5 PHS cases prescribed rotigotine. If a PD patient takes a large dose of LD and/or takes multiple antiparkinsonian drugs, we may need to be cautious of the development of PHS. This study has some limitations. First, only patients from one institution (a university hospital) were involved, and the number of patients was not large. Because the sample size was small, we may not have been able to find significant correlation between rotigotine administration and the development of PHS. In contrast to previous reports [5], [6], our study showed that age was negatively associated with PHS. It is also possible that younger patients manage their medication without support from those around them, which may ultimately lead to poor medication compliance. The small sample size and/or facility bias (one university hospital) may have caused these conflicting results. Owing to the small sample size, it was also necessary to narrow down the factors for multivariable analysis. Generally, the m H&Y stage, LD dose, and LED are associated with PD duration. Therefore, we did not include these three factors in the multivariable analysis. Furthermore, the ropinirole transdermal patch, another transdermal dopamine agonist, was not fully investigated because only a few patients took it in this study. A comparison of rotigotine and ropinirole transdermal patch will be necessary in the future. Second, we may not have accurately analyzed medication compliance in these patients immediately before emergency hospitalization because this was a retrospective study. Further prospective multicenter studies with larger numbers of patients with both PD and PHS are necessary. In conclusion, maintaining good medication compliance is crucial for suppressing the onset of PHS in patients with PD, and we consider that rotigotine may be a good option. Physicians should consider details of antiparkinsonian medications from the perspective of improving medication compliance to suppress the onset of PHS. CRediT authorship contribution statement Shohei Watanabe: Writing – original draft, Validation, Project administration, Methodology, Investigation, Data curation, Conceptualization. Ayano Hasuike: Data curation. Hosho Morishita: Data curation. Koji Yagi: Data curation. Eiko Fujiwara: Data curation. Daisuke Yamanaka: Data curation. Shuhei Kasama: Data curation. Masataka Igeta: Validation, Methodology, Formal analysis. Takashi Kimura: Validation, Supervision, Project administration. Funding This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.